Evaluation of the use of dried blood samples for the detection of the 4-doping product vadadustat (Vafseo®)

Assessment of dried blood spot sampling for detecting the doping agent vadadustat (Vafseo®) in healthy volunteers following a single oral dose: an open-label study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN13981390

Enrollment

Registered

2026-06-12

Start date

2026-09-01

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The detection of vadadustat in dried blood spots (DBS) after a single oral administration. Other

Interventions

Single oral administration of 150 mg of Vadadustat (Vasfeo®) Before taking 150 mg of vadadustat orally, urine, venous and capillary blood samples are taken. Age, weight, and height will be recorded a

Eligibility

Sex/Gender

All

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Age between 18 and 40 years old 2. Healthy 3. Capacity to understand the study protocol 4. The participant has signed the informed consent statement

Exclusion criteria

Exclusion criteria: 1. Have an elite athlete license 2. Use of concomitant medication 3. Known liver and/or kidney diseases 4. Active cancer 5. History of thrombo-embolic events 6. History of cardiovascular events 7. Known diabetes 8. Pregnancy or current breastfeeding

Countries

Switzerland

Contacts

Public ContactMenno Pruijm

nicolas.leuenberger@chuv.ch+41 (0)21 314 1358

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Jun 29, 2026